Recurrent glioblastoma
Conditions
Interventions
None listed
Sponsors
Oncopeptides AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Outcome results
None listed
A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: May 16, 2026